VERNON HILLS, Ill.--(BUSINESS WIRE)--March 23, 2006--Applied NeuroSolutions, a biopharmaceutical company focused on diagnostics and novel therapeutic targets for treatment of Alzheimer’s disease (AD), today announced results for the full-year ended December 31, 2005. Total revenues for the twelve months ended December 31, 2005 increased 90% to $480,000 compared to $253,000 in 2004. Net loss for the 2005 full-year was $2.62 million, or $0.028 per share, versus $2.80 million, or $0.032 per share, in 2004. Applied NeuroSolutions ended the year with $1.66 million in cash. The company currently spends approximately $675,000 each quarter.
